|
|
|
| Clinical features of drug -induced liver failure：forty-four cases report |
| DONG Peiling LI Hongjing GAO Jirong |
| Liver Department, Beijing You'an Hospital, Capital Medical University, Beijing 100069, China |
|
|
|
|
Abstract Objective To analyze the clinical features, prognosis associated with factors retrospectively in order to improve the curative efficacy of drug-induced liver failure. Methods From December 2012 to December 2014, forty-four clinical data of patients with drug-induced liver failure in Beijing You'an Hospital, Capital Medical University were reviewed according to the drug history, clinical features, laboratory tests, complications and prognosis associated factors. Results The incidence of drug-induced liver failure in the female was higher than that of male, the onset age was mainly middle-aged and old. The predominant etiological drugs were the traditional Chinese medicine (56.8%) and anti-tubercular agent (18.2%). The predominant types of liver failure were acute liver failure (9.1%) and sub-acute liver failure (86.4%), and the common complications were ascites, electrolyte disturbance and hepatic encephalopathy. 7 patients were died (15.9%). The incidences of hepatic encephalopathy and electrolyte disturbance in the healing group was lower than those of ineffective group, with highly statistically significant differences (P ＜ 0.01). The prothrombin activity level in the healing group was higher than those of ineffective group, with highly statistically significant differences (P ＜ 0.01). There were no significant differences in total bilirubin, cholinesterase and total cholesterol (P ＞ 0.05). Conclusion Traditional Chinese medicine and anti-tubercular agent are the main etiologies of drug-induced liver failure. The onset of hepatic encephalopathy and electrolyte disorder prompting poor prognosis. Clinical doctors should attach great importance to drug damage potential of liver, especially in the process of using traditional Chinese medicine and the liver function should be monitored regularly.
|
|
|
|
|
|
[1] 中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组．肝衰竭诊治指南（2012年版）[J].中华肝脏病杂志，2013，21（3）：177-183.
[2] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志，2015，31（11）：1752-1768.
[3] 美国胃肠病学院（ACG，American College of Gastroenterology）.2014 ACG 药物性肝损伤诊断和管理临床指南[J].Am J Gastroenterol，2014，109（7）：950-966.
[4] 茅益民.解读ACG临床指南：“特异质型药物性肝损伤的诊断和管理”[J].胃肠病学，2015，20（4）：193-198.
[5] 杨方集，彭亮，高志良.乙型肝炎慢加急性肝衰竭诊疗的新策略与新进展[J].中华临床感染病杂志，2017，10（2）：101-106.
[6] 宋海波，韩玲.中药肝损伤的流行特点、风险因素及评价[J].中国药理学与毒理学杂志，2016，30（4）：291-305.
[7] 刘成海，朱春雾.中草药相关药物性肝损伤的流行特点、主要原因与诊断评估[J].临床肝胆病杂志，2017，33（5）：829-832.
[8] 刘平.中草药的肝损伤问题[J].中华肝脏病杂志，2004， 12（4）：243.
[9] Goldberg DS， Forde KA，Carbonari DM，et al. Population-representative Incidence of Drug-induced Acute Liver Failure Based on an Analysis of an Integrated Healthcare System [J]. Gastroenterology，2015，148（7）：1353-1361.
[10] 于乐成，范晔，陈成伟.药物性肝损伤慢性化判断标准：3或6个月还是1年?[J].肝脏，2017，22（2）：97-100.
[11] 郑俊福，刘晖，董培玲.药物性肝炎66例Maria评分与病理关系[J].中国误诊学杂志，2010，10（28）：6971.
[12] 郭玉明，王伽伯，朱云，等.《中草药相关肝损伤临床诊疗指南》诊疗策略解读[J].中草药，2016，47（20）：3551-3559.
[13] 李梦楠，王玉平，周永宁.药物性肝损伤的研究进展[J].胃肠病学和肝病学杂志，2016，25（7）：828-831.
[14] Hillman L，Gottfried M， Whitsett M，et al. Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury [J]. Am J Gastroenterol，2016，111（7）：958-965.
[15] 李娟，张云丽，张文丽，等.229例肝功能衰竭病因及转归分析[J].肝脏，2016，21（4）：276-279.
[16] 刘政芳，黄伟，李芹.慢加急性肝衰竭合并自发性细菌性腹膜炎的危险因素分析[J].临床肝胆病杂志，2017， 33（4）：719-722.
[17] 安慧茹，吴雪琼.抗结核药物性肝损害研究进展[J].中国抗生素杂志，2010，35（10）：727-733.
[18] 郭瑶雪，邓晔，李春，等.异烟肼致线粒体损伤引起药物性肝损伤研究进展[J].中国临床药理学与治疗学，2015， 20（3）：356-360.
[19] Singh D，Cho WC，Upadhyay G. Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants：An Overview [J]. Front Physiol，2015，30（6）：363.
[20] 何婷婷，宫嫚，白云峰，等.2种药物性肝损伤诊断指南的应用分析[J].中国中药杂志，2016，41（16）：3096-3099. |
|
|
|
